View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 17, 2019updated 23 Dec 2019 11:57am

doc.ai’s digital health trial to improve Epilepsy treatment

Healthcare startup doc.ai has launched the Epilepsy Digital Health Trial to improve treatment options for the condition and to test how artificial intelligence (AI) can help create a predictive and accurate treatment for curing diseases.

Healthcare startup doc.ai has launched the Epilepsy Digital Health Trial to improve treatment options for the condition and to test how artificial intelligence (AI) can help create a predictive and accurate treatment for curing diseases.

Free Whitepaper
img

Never Trust, Always Verify: Is Zero Trust the Next Big Thing in Cybersecurity?

Cyberattacks continue to rise every year and no sector seems to be immune. Hackers target sensitive information such as organizational, client, and financial data, as well as intellectual property (IP) and proprietary functions. As digital transformation becomes a top priority for many organizations, traditional perimeter-based security models are no longer sufficient to address the growing cybersecurity concerns. Against the backdrop, enterprises explore zero trust as it takes a micro-level approach to authenticate and approve access at every point within a network. Reasons to read: The cybersecurity landscape is swiftly changing, and businesses need more awareness to meet the evolving change. The report highlights the current state of play and the future potential of the zero trust approach in cybersecurity to protect critical digital infrastructure of enterprises across sectors such as financial services, healthcare, telecom, and transportation, among others. Read our report and gather insights on the following topics:
  • Traditional vs zero trust protection
  • Key advantages and solution providers
  • Major industries and key players
  • Drivers and challenges
  • Top funded startups and Mergers & Acquisitions
  • Implementation challenges
by GlobalData
Enter your details here to receive your free Whitepaper.

doc.ai has collaborated with the Stanford University School of Medicine and the Stanford Epilepsy Center to deploy and test AI to develop a predictive treatment model.

Epilepsy is a neurological disorder characterised by recurrent seizures. It affects approximately 65 million people worldwide and 3.4 million in the US.

doc.ai CEO De Brouwer said: “We’re testing our AI capabilities to help clinicians and their patients to find the optimal anti-seizure drug for an individual.

“Utilising AI and real-world data from multiple sources for medical research is a step forward in medicine. It has the potential to reduce costs and increase participation by reaching users on the devices they use every day.”

The Epilepsy Digital Health Trial is an at-home, HIPAA-compliant and IRB-approved trial seeking to enrol up to 1,000 eligible participants from September 2019 to September 2020.

Patients will be enrolled through the doc.ai app.

They will keep an online diary to track their seizure episodes and medication side effects for up to three months.

The study will also gather and analyse patients’ health data, including personal-omics information such as the genome (DNA test provided by Kailos) and the phenome to capture physical traits.

It will also analyse patients’ physiome for exercise and activity tracking, pharmacome or medication tracking, and the exposome.

The digital health trial leverages doc.ai AI technologies, which includes natural language processing for automatic import of medical bottled photographs captured by the participants.

Kailos Genetics chief scientific officer Troy Moore said: “doc.ai has a robust multi-omics data pipeline, and we’re proud to contribute DNA tests free of charge to advance medicine.”

Upon completion of the trial, participants will receive an individualised report of gathered data to share with their physicians.

The Epilepsy Digital Health Trial is now open for enrolment for the US patients aged between 18 and 100 years, who are identified with epilepsy and have a smartphone using the iOS operating system.

doc.ai also has two other digital health trials open to improve the precision in treatment of inflammatory bowel disease and allergies.

Related Companies

Free Whitepaper
img

Never Trust, Always Verify: Is Zero Trust the Next Big Thing in Cybersecurity?

Cyberattacks continue to rise every year and no sector seems to be immune. Hackers target sensitive information such as organizational, client, and financial data, as well as intellectual property (IP) and proprietary functions. As digital transformation becomes a top priority for many organizations, traditional perimeter-based security models are no longer sufficient to address the growing cybersecurity concerns. Against the backdrop, enterprises explore zero trust as it takes a micro-level approach to authenticate and approve access at every point within a network. Reasons to read: The cybersecurity landscape is swiftly changing, and businesses need more awareness to meet the evolving change. The report highlights the current state of play and the future potential of the zero trust approach in cybersecurity to protect critical digital infrastructure of enterprises across sectors such as financial services, healthcare, telecom, and transportation, among others. Read our report and gather insights on the following topics:
  • Traditional vs zero trust protection
  • Key advantages and solution providers
  • Major industries and key players
  • Drivers and challenges
  • Top funded startups and Mergers & Acquisitions
  • Implementation challenges
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena